"Safety, Tolerability, and Efficacy of TAR-200 in Patients with Muscle-" by Mark D. Tyson, David Morris et al.
 

Safety, Tolerability, and Efficacy of TAR-200 in Patients with Muscle-Invasive Bladder Cancer Who Refused or Were Unfit for Curative-Intent Therapy: A Phase 1 study

Document Type

Conference Proceeding

Publication Date

11-2-2022

Comments

Western Section American Urological Association (AUA) Meeting ; Oct 30- Nov 4, 2022 ;Kauai HI.

This document is currently not available here.

Share

COinS